Litigation over GLP-1 drugs such as Ozempic and Wegovy is moving into the expert phase of the case with several key deadlines approaching in the coming months.
Judge Karen Marston, who oversees more than 3,300 lawsuits in Pennsylvania federal court, set April 10, 2026, as the deadline for all expert depositions to be finished. The lawyers on both sides will then submit motions for summary judgment by April 30, with a decision on the motions expected later this year. In a complex pharmaceutical case like this, expert opinions are required on certain topics such as how the GLP-1 drugs cause patients to sustain stomach injuries such as gastroenteritis, and whether the drug’s labeling adequately warned of these injuries.
The defendants in these cases are weight loss drug manufacturers Novo Nordisk and Eli Lilly. The semaglutide medications, which are FDA approved treatments for type 2 diabetes, have helped many people treat their diabetes and lose weight. However, some patients are reporting terrible side effects that they had no idea the drug could cause.
GLP-1 Lawsuits on Separate Tracks
The lawsuits against GLP-1 drug manufacturers fall into two main categories. One multi-district litigation (MDL) proceeding alleges the drugs can trigger a host of stomach conditions, including gastroparesis, which is a non-curable form of gastrointestinal paralysis. A second multi-district litigation proceeding claims that the GLP-1 drugs can cause vision-threatening eye conditions, including non-arteritic anterior ischemic optic neuropathy (NAION), which occurs when blood flow to the optic nerve is blocked and causes sudden irreversible blindness. The first trials in the gastroparesis track won’t happen until Judge Marston rules on the summary judgment motions. These so-called dispositive motions could determine whether any of the GLP-1 cases will be allowed to advance to trial. The NAION eye injury cases are not as advanced in litigation. Judge Marston will hold a “science day” on June 2, 2026, where the parties will present the latest evidence about the link between GLP-1 drugs and optic neuropathy.
Call us for a Free Case Evaluation
Our law firm represents Ozempic and Wegovy patients all over the country. If you or a loved one suffered injuries from Ozempic or other GLP-1 weight loss drugs, you may be entitled to financial compensation. To review your case, contact the lawyers at Alex Davis Law or call 502-882-6000 to schedule a free consultation today.